Stay updated on Nivolumab in IDH-Mutant Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in IDH-Mutant Gliomas Clinical Trial page.

Latest updates to the Nivolumab in IDH-Mutant Gliomas Clinical Trial page
- Check3 days agoChange DetectedThe page’s footer now identifies the ClinicalTrials.gov site revision as v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check10 days agoChange DetectedThe ClinicalTrials.gov record for NCT03718767 is displayed with study details, eligibility, outcomes, investigators, record dates, and supporting documents, replacing the 403 error view.SummaryDifference60%

- Check17 days agoChange DetectedThe site revision displayed in the footer changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check31 days agoChange DetectedAn NIH notice about its website transition and updated terminology appears above the page, while the clinical trial record still displays a 403 Forbidden error. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check45 days agoChange DetectedThe footer revision number was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check52 days agoChange DetectedRemoved the 403 Forbidden error screen HTML and related elements, addressing a core access issue that previously blocked viewing the study details. This change suggests the page can render the study details normally without displaying an error screen.SummaryDifference0.5%

Stay in the know with updates to Nivolumab in IDH-Mutant Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in IDH-Mutant Gliomas Clinical Trial page.